Design Therapeutics Q4 2021 Earnings Report
Key Takeaways
Design Therapeutics reported its Q4 and full year 2021 financial results, highlighting the clearance of the IND for DT-216 and progress in developing GeneTACTM molecules for myotonic dystrophy type-1 and Fuchs endothelial corneal dystrophy. The company ended the year well-capitalized with $384.1 million in cash and investments.
IND Application for FA Development Candidate, DT-216, Cleared by the FDA.
Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of FECD to be Presented at ARVO 2022.
Strengthened Leadership Team with Appointment of Chief Medical Officer.
Cash, cash equivalents and marketable securities were $384.1 million as of December 31, 2021.
Design Therapeutics
Design Therapeutics
Forward Guidance
Statements in this press release that are not purely historical in nature are "forward-looking statements".